Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alumis (Nasdaq: ALMS) reported a narrower third-quarter 2026 net loss while advancing envudeucitinib toward a psoriasis regulatory submission. Net loss was $94.9 million, versus $110.8 million a year earlier; collaboration revenue declined to $1.9 million from $2.1 million. Research and development expenses fell to $80.8 million from $97.8 million. Cash, cash equivalents and marketable securities totaled $431.3 million at September 30, 2026; Alumis expects funding to last into fourth-quarter 2027.
Psoriasis data included 54% complete skin clearance at Week 48. Alumis remains on track for a fourth-quarter 2026 FDA application. The LUMUS lupus trial missed its primary and secondary endpoints overall, although responses were observed in a prespecified high-interferon subgroup. Alumis plans regulatory discussions and evaluation of development options, plus a Phase 2 Parkinson’s biomarker trial of A-005 in 2027.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointThird-quarter net loss narrowed to $94.9 million from $110.8 million a year earlier.
- Moderate pointThird-quarter research and development expenses fell to $80.8 million from $97.8 million a year earlier.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Alumis expects $431.3 million in September 30, 2026 liquidity to fund operations and capital expenditures into fourth-quarter 2027.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Alumis remains on track for a psoriasis FDA application in fourth-quarter 2026.
- Minor pointEnvudeucitinib achieved 54% PASI 100, meaning complete skin clearance, at Week 48 in psoriasis.
16 minor points
- Minor pointONWARD3 scalp results showed over 80% maintained clear or almost clear scalp skin at 48 weeks.
- Minor pointONWARD1/2 itch results showed approximately one-third achieved clinically meaningful improvement as early as Week 2.
- Minor pointONWARD1/2 itch results showed about 40% achieved complete resolution and approximately 60% minimal or no itch by Week 16.
- Minor pointONWARD3 itch results showed nearly 80% sustained clinically meaningful improvement through Week 48.
- Minor pointONWARD1/2 quality-of-life results showed approximately 50% had minimal or no daily impact from psoriasis by Week 12.
- Minor pointONWARD3 quality-of-life results showed more than 70% maintained minimal or no daily impact at 48 weeks.
- Minor pointPatients switching from placebo or apremilast reached improvements comparable to continuous treatment at Week 48.
- Minor point. Forward-looking: it has not happened yet and may not happen.Alumis anticipates two-year Phase 2 safety data for envudeucitinib in psoriasis in fourth-quarter 2026.
- Minor pointLUMUS prespecified high-interferon subgroup showed responses on the primary and key secondary endpoints.
- Minor pointLUMUS demonstrated dose-dependent interferon-pathway suppression, maximal at 40 mg twice daily.
- Minor pointEnvudeucitinib was well tolerated in LUMUS, with no new safety signals.
- Minor point. Forward-looking: it has not happened yet and may not happen.Alumis plans end-of-Phase 2 regulatory interactions and evaluation of lupus development options.
- Minor pointA-005 Phase 1 results showed central nervous system penetration, maximal peripheral target inhibition and tolerability.
- Minor point. Forward-looking: it has not happened yet and may not happen.Alumis plans an A-005 Phase 2 Parkinson’s biomarker trial in 2027.
- Minor pointNine-month research and development expenses fell to $247.669 million from $303.213 million a year earlier.
- Minor pointNine-month general and administrative expenses fell to $62.157 million from $76.267 million a year earlier.
Negative
- Major pointLUMUS Phase 2b missed primary and secondary endpoints in the overall lupus trial population.
- Moderate pointNine-month revenue fell to $5.310 million from $22.121 million a year earlier.
- Moderate pointNine-month net loss widened to $330.155 million from $150.394 million a year earlier.
- Moderate pointNine-month intangible asset impairment loss was $41.824 million, versus none a year earlier. 4.9% of market cap
- Minor pointAlumis said high-interferon patients were unexpectedly under-represented in LUMUS, reducing overall trial response rates.
2 minor points
- Minor pointThird-quarter collaboration revenue declined to $1.9 million from $2.1 million a year earlier.
- Minor pointThird-quarter general and administrative expenses rose to $20.2 million from $19.5 million a year earlier.
Key Figures
- PASI 100 response rate
- 54%
- Week 48
- Scalp clearance
- Over 80%
- ONWARD3 patients maintained clear or almost clear scalp skin at 48 weeks
- Clinically meaningful itch reduction
- Approximately one-third
- Achieved by Week 2 in ONWARD1/2
- Cash, cash equivalents and marketable securities
- $431.3 million
- As of September 30, 2026
- Cash runway
- Into the fourth quarter of 2027
- Company's current operating plan
- Research and development expenses
- $80.8 million
- Q3 2026, compared with $97.8 million in Q3 2025
- Net loss
- $94.9 million
- Q3 2026, compared with $110.8 million in Q3 2025
- Collaboration revenue
- $1.9 million
- Q3 2026, compared with $2.1 million in Q3 2025
Previous Earnings Reports
-
Q2 report cited ONWARD3 PASI 90 and PASI 100 response rates of 75% and 54%.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
tyk2 inhibitor medical
pasi medical
bicla medical
pharmacodynamic medical
new drug application regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
– New Phase 3 data demonstrated rapid and durable improvements in plaque psoriasis burden, adding to envudeucitinib's differentiated clinical profile, including the highest publicly reported Week 48 PASI 100 response rate among existing and investigational oral psoriasis therapies –
– Alumis remains on track to submit an NDA for envudeucitinib in moderate-to-severe plaque
psoriasis in 4Q 2026 –
– Announced topline results from the LUMUS Phase 2b trial for envudeucitinib in systemic lupus erythematosus (SLE) –
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today reported financial results for the quarter ended September 30, 2026, and highlighted recent business updates and upcoming milestones.
“Each additional readout from the ONWARD program has strengthened the consistent body of evidence supporting envudeucitinib’s highly competitive profile in moderate-to-severe plaque psoriasis,” said Martin Babler, President and Chief Executive Officer of Alumis. “The new data presented in October showed early and durable improvement across scalp disease severity, itch resolution, and quality of life measures, building on a
Third Quarter 2026 and Recent Highlights
Envudeucitinib: a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate-to-severe plaque psoriasis
- New data presented at the 26th Annual Fall Clinical Dermatology Conference demonstrated early and durable improvements across scalp disease severity, itch resolution, and quality of life measures. These data build on envudeucitinib’s high-threshold skin clearance observed across the ONWARD program, including a
54% Psoriasis Area and Severity Index (PASI) 100 response rate at Week 48 (LINK TO PR). - High rate of scalp clearance: Over
80% of patients in ONWARD3 maintained clear or almost clear scalp skin (scalp-specific Physician Global Assessment [ss-PGA] 0/1) at 48 weeks. - Rapid, robust and sustained itch relief: In ONWARD1/2, approximately one-third of patients—including those with moderate-to-severe scalp disease (ss-PGA ≥3)—achieved clinically meaningful itch reduction (≥4-point NRS improvement) as early as Week 2. By Week 16, about
40% reached complete itch resolution (NRS 0) and approximately60% reported minimal or no itch (NRS 0/1). In ONWARD3, nearly80% of patients sustained clinically meaningful itch reduction through Week 48. - Early, durable quality-of-life improvements: Approximately
50% of patients in ONWARD1/2 achieved a Dermatology Life Quality Index (DLQI) score of 0 or 1 by Week 12, reflecting minimal to no impact of psoriasis on daily activities. In ONWARD3, more than70% of patients maintained DLQI 0/1 at 48 weeks. - Rapid crossover convergence: Patients switching from placebo or apremilast achieved rapid improvements across primary and key secondary endpoints, comparable to those continuously treated at Week 48.
- Alumis remains on track to submit its New Drug Application to the FDA for envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of 2026.
Envudeucitinib: Systemic Lupus Erythematosus (SLE)
- Phase 2b LUMUS trial of envudeucitinib for the treatment of moderate-to-severe systemic lupus erythematosus (SLE) did not meet its primary and secondary endpoints in the overall trial population (LINK TO PR).
- Robust clinical responses were observed in a prespecified subgroup analysis of patients with high interferon gene signature (IFNGS-high), including on the primary endpoint of British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) and key secondary endpoints of Cutaneous Lupus Erythematosus Disease Area and Severity Index 50 (CLASI-50), SLE Responder Index 4 (SRI-4), and Lupus Low Disease Activity State (LLDAS).
- IFNGS-high patients represent the majority of moderate-to-severe SLE cases. In LUMUS, they were unexpectedly under-represented, reducing response rates in the overall trial population.
- Pharmacodynamic data from LUMUS confirmed robust dose-dependent interferon-pathway target engagement, with maximal suppression at the highest dose, 40 mg twice daily.
- Envudeucitinib was well tolerated in LUMUS, with no new safety signals.
- Alumis plans to conduct end-of-Phase 2 regulatory interactions and evaluate development options.
TYK2 Franchise and Pipeline Update
- Alumis plans to initiate a Phase 2 biomarker trial for A-005, its central nervous system (CNS) penetrant TYK2 inhibitor, in patients with Parkinson’s disease, in 2027. In a Phase 1 healthy volunteer study, A-005 was well-tolerated, achieved maximal target inhibition in the periphery, and demonstrated the ability to penetrate the CNS.
Anticipated Milestones
- Envudeucitinib in Moderate-to-Severe Plaque Psoriasis
- Long-term data: Phase 2, two-year safety data (4Q 2026).
- NDA submission (4Q 2026).
- A-005
- Initiation of Phase 2 biomarker trial in Parkinson’s disease (2027).
- Initiation of Phase 2 biomarker trial in Parkinson’s disease (2027).
Third Quarter 2026 Financial Results
- As of September 30, 2026, Alumis had cash, cash equivalents and marketable securities of
$431.3 million . - Revenue consisted of collaboration revenue of
$1.9 million for the quarter ended September 30, 2026, compared to collaboration revenue of$2.1 million for the quarter ended September 30, 2025, related to the collaboration and licensing agreement with Kaken Pharmaceutical Co., Ltd. - Research and development expenses were
$80.8 million for the quarter ended September 30, 2026, compared to$97.8 million for the quarter ended September 30, 2025. The decrease was primarily driven by lower clinical trial and contract research costs reflecting the progression of the envudeucitinib clinical program following completion of the pivotal Phase 3 ONWARD1 and ONWARD2 clinical trials in patients with moderate-to-severe plaque psoriasis, partially offset by an increase in clinical trial and contract research costs for the Phase 3 ONWARD3 clinical trial. - General and administrative expenses were
$20.2 million for the quarter ended September 30, 2026, compared to$19.5 million for the quarter ended September 30, 2025. The increase was primarily attributable to costs related to launch preparation efforts and an increase in personnel-related expenses for the quarter ended September 30, 2026, partially offset by severance and transaction costs related to the merger with ACELYRIN, Inc. and legal costs in the quarter ended September 30, 2025. - Net loss was
$94.9 million for the quarter ended September 30, 2026, compared to net loss of$110.8 million for the quarter ended September 30, 2025.
Financial Guidance
- Based on the Company’s current operating plan, Alumis continues to anticipate that its existing cash, cash equivalents and marketable securities as of September 30, 2026 are sufficient to fund operating expenses and capital expenditure requirements into the fourth quarter of 2027.
About Alumis
Alumis is a late-stage biopharma company developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, consisting of envudeucitinib for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases, such as Parkinson’s disease. In addition, the pipeline includes several preclinical programs identified through this precision approach. For more information, visit www.alumis.com or follow us on LinkedIn or X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and similar expressions intended to identify forward-looking statements. All statements contained in this press release other than statements of historical fact are forward-looking statements, including without limitation statements regarding: Alumis’ plans and anticipated timing for submitting an NDA for envudeucitinib in the fourth quarter of 2026; the therapeutic potential of TYK2 inhibition across immune-mediated, neuroinflammatory and neurodegenerative diseases and the potential multi-indication opportunity for envudeucitinib; the advancement of Alumis’ clinical pipeline including its plans to commence a Phase 2 biomarker study for A-005; the timing and results of clinical data readouts in its ongoing clinical trials, including long-term safety data in moderate-to-severe plaque psoriasis (PsO); the differentiated clinical profile of envudeucitinib and its potential to be a leading oral therapy in PsO; implications of the LUMUS IFNGS-high subgroup results for further development of envudeucitinib in SLE and Alumis’ plans to engage regulators regarding Phase 3 development in SLE; Alumis’ expectations regarding the sufficiency of its cash, cash equivalents and marketable securities to fund its operating expenses and capital expenditure requirements, including its anticipated cash runway; and Alumis’ future plans, strategy, prospects and anticipated milestones, as well as the assumptions underlying any of the foregoing. Forward-looking statements are based on Alumis’ current expectations, estimates, assumptions and projections as of the date of this press release and are subject to significant risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such statements. Readers should not place undue reliance on these forward-looking statements, and are cautioned that actual results, timing, safety, efficacy, performance or events and circumstances may differ materially from those expressed or implied in Alumis’ forward-looking statements due to a variety of risks and uncertainties including, without limitation, whether regulatory authorities accept for filing Alumis’ planned NDA submission as well as determine that envudeucitinib demonstrates an acceptable safety and efficacy profile and grant regulatory approval in moderate-to-severe plaque psoriasis; the timing and results of clinical trials; Alumis’ ability to obtain regulatory approval of and ultimately commercialize its product candidates; changes in Alumis’ operating plans and capital requirements that could reduce its anticipated cash runway; Alumis’ ability to obtain sufficient additional funding when needed and continue as a going concern; and Alumis’ ability to obtain, maintain and enforce intellectual property protection for its programs and product candidates. Additional information regarding these and other risks and uncertainties is contained under the heading “Risk Factors” and elsewhere in Alumis’ filings with the Securities and Exchange Commission (SEC), including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and subsequent filings with the SEC. Alumis explicitly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.
| ALUMIS INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| (in thousands) | 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Revenue: | ||||||||||||||||
| License revenue | $ | — | $ | — | $ | — | $ | 17,389 | ||||||||
| Collaboration revenue | 1,907 | 2,066 | 5,310 | 4,732 | ||||||||||||
| Total revenue | 1,907 | 2,066 | 5,310 | 22,121 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development expenses | 80,792 | 97,836 | 247,669 | 303,213 | ||||||||||||
| General and administrative expenses | 20,191 | 19,522 | 62,157 | 76,267 | ||||||||||||
| Intangible assets impairment loss | — | — | 41,824 | — | ||||||||||||
| Total operating expenses | 100,983 | 117,358 | 351,650 | 379,480 | ||||||||||||
| Loss from operations | (99,076 | ) | (115,292 | ) | (346,340 | ) | (357,359 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Gain on bargain purchase | — | — | — | 187,907 | ||||||||||||
| Interest income | 4,304 | 4,594 | 14,601 | 10,633 | ||||||||||||
| Other income (expenses), net | (109 | ) | (54 | ) | (173 | ) | (136 | ) | ||||||||
| Total other income (expense), net | 4,195 | 4,540 | 14,428 | 198,404 | ||||||||||||
| Net loss before income taxes | (94,881 | ) | (110,752 | ) | (331,912 | ) | (158,955 | ) | ||||||||
| Income tax benefit | — | — | 1,757 | 8,561 | ||||||||||||
| Net loss | $ | (94,881 | ) | $ | (110,752 | ) | $ | (330,155 | ) | $ | (150,394 | ) | ||||
| Other comprehensive income (loss): | ||||||||||||||||
| Unrealized gain (loss) on marketable securities, net | (47 | ) | 212 | (918 | ) | 194 | ||||||||||
| Total comprehensive loss | $ | (94,928 | ) | $ | (110,540 | ) | $ | (331,073 | ) | $ | (150,200 | ) | ||||
| ALUMIS INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) | ||||||||
| September 30, | December 31, | |||||||
| (in thousands) | 2026 | 2025 | ||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 57,691 | $ | 89,670 | ||||
| Restricted cash | — | 82 | ||||||
| Marketable securities, current | 373,647 | 218,831 | ||||||
| Research and development prepaid expenses | 3,437 | 2,909 | ||||||
| Other prepaid expenses and current assets | 7,815 | 6,740 | ||||||
| Total current assets | 442,590 | 318,232 | ||||||
| Restricted cash, non-current | 1,388 | 1,301 | ||||||
| Property and equipment, net | 16,427 | 18,190 | ||||||
| Intangible assets | 9,135 | 50,959 | ||||||
| Operating lease right-of-use assets, net | 16,744 | 16,971 | ||||||
| Other assets, non-current | 2,427 | 6,287 | ||||||
| Total assets | $ | 488,711 | $ | 411,940 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 8,926 | $ | 10,106 | ||||
| Research and development accrued expenses | 40,243 | 34,781 | ||||||
| Other accrued expenses and current liabilities | 18,331 | 22,303 | ||||||
| Deferred revenue, current | 6,876 | 1,458 | ||||||
| Operating lease liabilities, current | 5,029 | 4,670 | ||||||
| Total current liabilities | 79,405 | 73,318 | ||||||
| Operating lease liabilities, non-current | 30,277 | 32,244 | ||||||
| Deferred tax liability | 384 | 2,140 | ||||||
| Deferred revenue, non-current | — | 2,611 | ||||||
| Other liabilities, non-current | 220 | 330 | ||||||
| Total liabilities | 110,286 | 110,643 | ||||||
| Stockholders’ equity: | ||||||||
| Preferred stock | — | — | ||||||
| Common stock | 13 | 10 | ||||||
| Additional paid-in capital | 1,611,173 | 1,202,975 | ||||||
| Accumulated other comprehensive income (loss) | (730 | ) | 188 | |||||
| Accumulated deficit | (1,232,031 | ) | (901,876 | ) | ||||
| Total stockholders’ equity | 378,425 | 301,297 | ||||||
| Total liabilities and stockholders’ equity | $ | 488,711 | $ | 411,940 | ||||
Alumis Contact Information
Teri Dahlman
Red House Communications
teri@redhousecomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.